Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: A multicenter experience

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 10, 2013, Pages 998-1004

  Laharie, D ^a   Filippi, J ^b   Roblin, X ^c   Nancey, S ^d   Chevaux, J B ^e   Hebuterne X ^b   Flourie B ^d   Capdepont, M ^a   Peyrin Biroulet, L ^e  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLECTOMY FREE SURVIVAL; COLON RESECTION; COLONOSCOPY; CONTROLLED STUDY; FAILURE FREE SURVIVAL; FEMALE; FOLLOW UP; HEALING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGMOIDOSCOPY; SURVIVAL; SURVIVAL RATE; TREATMENT FAILURE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; FRANCE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84876486013     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12289     Document Type: Article

References (23)

1. Danese S, Fiocchi C,. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25.
2. Rutgeerts P, Vermeire S, Van Assche G,. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453-5.
3. Peyrin-Biroulet L, Ferrante M, Magro F, et al,. Results from the 2nd scientific workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-83.
4. Froslie KF, Jahnsen J, Moum BA, et al,. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
5. Ardizzone S, Cassinotti A, Duca P, et al,. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-9.
6. Parente F, Molteni M, Marino B, et al,. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis?: a prospective study. Am J Gastroenterol 2010; 105: 1150-7.
7. Colombel JF, Rutgeerts P, Reinisch W, et al,. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
8. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al,. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
9. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
10. Panaccione R, Ghosh S, Middleton S, et al,. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J Crohn Colitis 2011; 5: S8.
11. Jarnerot G, Hertervig E, Friis-Liby I, et al,. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
12. Laharie D, Bourreille A, Branche J, et al,. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
13. Ferrante M, Vermeire S, Fidder H, et al,. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn Colitis 2008; 2: 219-25.
14. Oussalah A, Evesque L, Laharie D, et al,. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617-25.
15. Stange EF, Travis SP, Vermeire S, et al,. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 (Suppl. 1): i1-15.
16. Satsangi J, Silverberg MS, Vermeire S, et al,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
17. Sandborn WJ, Rutgeerts P, Feagan BG, et al,. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-60.
18. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
19. De Vos M, Dewit O, D'Haens G, et al,. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis 2012; 6: 557-62.
20. Lewis JD,. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-26.
21. Ordas I, Rimola J, Garcia-Bosch O, et al,. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 2012 [Epub ahead of print].
22. Riley SA, Mani V, Goodman MJ, et al,. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
23. Bitton A, Peppercorn MA, Antonioli DA, et al,. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.